切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2016, Vol. 04 ›› Issue (02) : 95 -98. doi: 10.3877/cma.j.issn.2095-5820.2016.02.008

所属专题: 文献

综述

脓毒症相关生物标志物研究进展
胡敏1,(), 王继贵1   
  1. 1. 410011 长沙,中南大学湘雅二医院检验科
  • 收稿日期:2016-04-19 出版日期:2016-05-28
  • 通信作者: 胡敏

Research advance on sepsis biomarkers

Min Hu1,(), Jigui Wang1   

  1. 1. Department of Clinical Laboratory, the Second Xiangya Hospital of Central South University, Changsha 410011, China
  • Received:2016-04-19 Published:2016-05-28
  • Corresponding author: Min Hu
  • About author:
    Corresponding author: Hu Min, Email:
引用本文:

胡敏, 王继贵. 脓毒症相关生物标志物研究进展[J/OL]. 中华临床实验室管理电子杂志, 2016, 04(02): 95-98.

Min Hu, Jigui Wang. Research advance on sepsis biomarkers[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2016, 04(02): 95-98.

在重症监护病房(intensive care units, ICUs)的患者中,脓毒症是最常见的死亡原因;近年来,针对脓毒症早期实验室诊断有很大进展;本文对脓毒症的流行病学及发病机理作简要概述,同时介绍用于脓毒症诊断的特殊的生物化学、血液学以及免疫学诊断方法。

Sepsis is the most common cause of death in non-coronary intensive care units (ICUs). It is a serious disease with a high mortality. In the past 10 years, progress has been made in early identification of septic patients. This article gives a short overview of the current epidemiology of sepsis, its pathogenesis and state-of-the-art knowledge on the use of specific biochemical, hematological and immunological parameters in its diagnostics.

1
Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes [J]. Expert Rev Anti-Infect Ther, 2012,10(6):701~706.
2
Martin G, brunkhorst fm, janes jm, et al. the international progress registry of patients with severe sepsis: drotrecogin alfa (activated) use and patients outcomes [J]. Crit Care, 2009, 3(3):R103.
3
Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference [J]. Intensive Care Med, 2003,29(4):530-538.
4
Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives [J]. Immunity, 2014,40(4):463-475.
5
Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach [J]. Lancet Infect Dis, 2013,13(3):260-268.
6
Dellinger RP. Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013,39(2):165-228.
7
Pierrakos C, Vincent JL. Sepsis biomarkers: a review [J]. Crit Care, 2010,14(1):R15.
8
Haran JP, Beaudoin FL, Suner S, et al. C-reactive Protein as predictor of bacterial infection among patients with an influenza-like illness [J]. Am J Emerg Med, 2013,31(1):137-144.
9
Pradhan S, Ghimire A, Bhattarai B, et al. The role of C-reactive protein as a diagnostic predictor of sepsis in a multidisciplinary Intensive Care Unit of a tertiary care center in Nepal[J]. Indian J Crit Care Med, 2016, 20(7):417-20.
10
Poddar B, Gurjar M, Singh S, et al. Reduction in procalcitonin level and outcome in critically ill children with severe sepsis/septic shock-A pilot study [J]. J Crit Care, 2016,12(36):230-233.
11
Schuetz P, Albrich W, Christ-Crain M, el al. Procalcitonin for guidance of antibiotic therapy [J]. Expert rev Anti Infect Therapy, 2010,8(5):575-587.
12
Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and Potential Therapeutic targets-an updated view [J]. Mediat Inflamm, 2013:165974.
13
Mierzchala M, Krzystek-Korpacka M, Gamian A, et al. Quantitative indices of dynamics in concentrations of lipopolysaccharide-binding protein (LBP) as prognostic factors in severe sepsis/septic shock patients-comparison with CRP and Procalcitonin [J]. Clin Biochem, 2011,44(5-6):357-363.
14
Elwady S, Botros SK, Sorour AE, et al. neutrophil CD64 as a diagnostic marker of sepsis in neonates [J]. J Investig Med, 2014, 62(3):644-649.
15
Iba T, Gando S, Murata A, et al. Predicting the severity of systemic inflammatory response syndrome(SIRDS)-associate coagulopathy with hemostatic molecular markers and vascular endothelial injury markers [J]. J Trauma, 2007,63(5):1093-1098.
16
Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome [J]. J Infect Chemother, 2011, 17(6):764-769.
17
Endo S, Suzuld Y, Takahashi G, et al. presepsim as a powerful monitoring tool for the Prognosis and treatmet of sepsis:a multicenter prospective study [J]. J Infect Chemother, 2014,20(1):30-34.
18
Cao Z, Robinson AS. The role of Proteomic in understanding biological mechanism of sepsis [J]. Proteomics Clin Appl, 2014,8(1-2):35-52.
[1] 杨桂清, 孟静静. 哺乳期亚临床乳腺炎的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 376-379.
[2] 庄燕, 戴林峰, 张海东, 陈秋华, 聂清芳. 脓毒症患者早期生存影响因素及Cox 风险预测模型构建[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 372-378.
[3] 董大红, 周明虎, 李芝朋, 许正峰. 碳青霉烯类抗生素联合呼吸机治疗肺部感染的临床疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 793-796.
[4] 张燕, 杨跃青, 邱峥. IgG 联合血清细胞因子对肺结核并发慢性肺曲霉菌病的诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 809-812.
[5] 傅红兴, 王植楷, 谢贵林, 蔡娟娟, 杨威, 严盛. 间充质干细胞促进胰岛移植效果的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 351-360.
[6] 赵月, 田坤, 张宗明, 郭震天, 刘立民, 张翀, 刘卓. 降钙素原对老年急性重度胆囊炎发生的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 801-806.
[7] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[8] 冯熔熔, 苏晓乐, 王利华. 慢性肾脏病患者并发心血管疾病相关生物标志物研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 273-278.
[9] 张晓青, 唐雯. 基于临床化验指标重新计算的生物标记物在预测腹膜透析患者预后中的作用研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 213-218.
[10] 陈曦, 吴宗盛, 郑明珠, 邱海波. 胸腺萎缩在脓毒症免疫紊乱中的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 379-383.
[11] 杨翔, 郭兰骐, 谢剑锋, 邱海波. 转录组学在脓毒症诊疗中的临床研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 384-388.
[12] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[13] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[14] 陈惠英, 邱敏珊, 邵汉权. 脓毒症诱发肠黏膜屏障功能损伤的风险因素模型构建与应用效果[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 448-452.
[15] 傅新露, 李之岳, 卢丹. 妊娠合并结肠癌穿孔致脓毒症休克一例并文献复习[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 227-231.
阅读次数
全文


摘要